OverviewChartNewsTraderScreen

ING Knock-Out RO/  DE000NG9CJY4  /

Frankfurt Zertifikate
9/6/2024  4:40:22 PM Chg.-0.100 Bid5:19:50 PM Ask5:19:50 PM Underlying Strike price Expiration date Option type
2.860EUR -3.38% -
Bid Size: -		 -
Ask Size: -		 ROCHE I 270.827 CHF 12/31/2078 Call
GlobeNewswire 8/26 First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborat...
GlobeNewswire 8/19 LIXTE Biotechnology Provides Update On Recent Activities and Developments
GlobeNewswire 8/8 Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
GlobeNewswire 8/8 Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Updat...
TeleTrader 7/25 Europe lower premarket as earnings pour in
TeleTrader 7/25 Roche's H1 sales at 29.85 billion Swiss francs
GlobeNewswire 6/27 Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
GlobeNewswire 6/18 Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire 6/14 LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire 6/11 Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
TeleTrader 5/27 Roche shuffles its executive committee
TeleTrader 5/16 Roche notes progress in obesity drug trial
GlobeNewswire 5/9 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire 5/7 Enable Injections Expands Strategic Partnership with Roche
TeleTrader 4/24 Roche's logs 14.4 billion Swiss francs in Q1 sales
GlobeNewswire 4/3 UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire 4/2 Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire 3/22 HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highl...
GlobeNewswire 3/14 Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire 2/26 Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire 2/21 REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...
GlobeNewswire 2/13 Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Busine...
TeleTrader 2/1 Roche's 2023 sales increase 1% to 58.7B Swiss francs
GlobeNewswire 1/29 Carmot Therapeutics Announces Completion of Acquisition by Roche
GlobeNewswire 1/3 US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Haltin...